5 Best Small Cap Pharma Stocks to Buy

Page 5 of 5

1. Pacira BioSciences, Inc. (NASDAQ:PCRX)

Number of Hedge Fund Investors in Q1 2023: 30

Pacira BioSciences, Inc. (NASDAQ:PCRX) develops customized drugs that are capable of targeting only select nerves as part of a pain management treatment. Like some other firms on our list, the stock is also down year to date and has lost 7% of its value so far. However, the shares are rated Strong Buy on average, and the average share price target of $61 provides a sizeable upside.

30 of the 943 hedge funds part of Insider Monkey’s Q1 2023 database had invested in Pacira BioSciences, Inc. (NASDAQ:PCRX). Israel Englander’s Millennium Management is the biggest investor with an investment worth $64.7 million.

Follow Pacira Biosciences Inc. (NASDAQ:PCRX)

Disclosure: None. You can also take a look at 11 High Growth Utility Stocks to Buy and 110 Undervalued Stocks to Buy According to Billionaire Joel Greenblatt.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Follow Insider Monkey on Twitter

Page 5 of 5